APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attention Deficit Hyperactivity Disorder Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026199 pages

Choose your research edition.

Industry ResearchAttention Deficit Hyperactivity Disorder Therapeutics Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Attention Deficit Hyperactivity Disorder Therapeutics Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Attention Deficit Hyperactivity Disorder Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Attention Deficit Hyperactivity Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Attention Deficit Hyperactivity Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Attention Deficit Hyperactivity Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Attention Deficit Hyperactivity Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Attention Deficit Hyperactivity Disorder Therapeutics include Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Purdue Parma, Noven Pharmaceuticals, Neos Therapeutics and Mallinckrodt, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Attention Deficit Hyperactivity Disorder Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Attention Deficit Hyperactivity Disorder Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Attention Deficit Hyperactivity Disorder Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Attention Deficit Hyperactivity Disorder Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Attention Deficit Hyperactivity Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Attention Deficit Hyperactivity Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Company

Takeda

Johnson & Johnson

Novartis

Eli Lilly

Tris Pharma

Purdue Parma

Noven Pharmaceuticals

Neos Therapeutics

Mallinckrodt

Amneal Pharmaceuticals

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Type

Stimulant

Non-stimulant

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Application

Hospital Pharmacy

Retail Pharmacy

Attention Deficit Hyperactivity Disorder Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attention Deficit Hyperactivity Disorder Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attention Deficit Hyperactivity Disorder Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attention Deficit Hyperactivity Disorder Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Attention Deficit Hyperactivity Disorder Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Attention Deficit Hyperactivity Disorder Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Attention Deficit Hyperactivity Disorder Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Stimulant Major Player Table 3. Non-stimulant Major Player Table 4. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacy Major Player Table 6. Retail Pharmacy Major Player Table 7. Attention Deficit Hyperactivity Disorder Therapeutics Industry Trends Table 8. Attention Deficit Hyperactivity Disorder Therapeutics Industry Drivers Table 9. Attention Deficit Hyperactivity Disorder Therapeutics Industry Opportunities and Challenges Table 10. Attention Deficit Hyperactivity Disorder Therapeutics Industry Restraints Table 11. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region (2021-2026) Table 14. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region (2027-2032) Table 16. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Players (2021-2026) Table 18. Global Attention Deficit Hyperactivity Disorder Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Attention Deficit Hyperactivity Disorder Therapeutics Key Players Headquarters & Area Served Table 20. Global Attention Deficit Hyperactivity Disorder Therapeutics Players, Product Type & Application Table 21. Global Attention Deficit Hyperactivity Disorder Therapeutics Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Attention Deficit Hyperactivity Disorder Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Type (2021-2026) Table 28. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Type (2027-2032) Table 29. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Application (2021-2026) Table 33. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Application (2027-2032) Table 34. Takeda Company Information Table 35. Takeda Business Overview Table 36. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Takeda Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 38. Takeda Recent Development Table 39. Johnson & Johnson Company Information Table 40. Johnson & Johnson Business Overview Table 41. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 43. Johnson & Johnson Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Novartis Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 48. Novartis Recent Development Table 49. Eli Lilly Company Information Table 50. Eli Lilly Business Overview Table 51. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 53. Eli Lilly Recent Development Table 54. Tris Pharma Company Information Table 55. Tris Pharma Business Overview Table 56. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 58. Tris Pharma Recent Development Table 59. Purdue Parma Company Information Table 60. Purdue Parma Business Overview Table 61. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 63. Purdue Parma Recent Development Table 64. Noven Pharmaceuticals Company Information Table 65. Noven Pharmaceuticals Business Overview Table 66. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 68. Noven Pharmaceuticals Recent Development Table 69. Neos Therapeutics Company Information Table 70. Neos Therapeutics Business Overview Table 71. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 73. Neos Therapeutics Recent Development Table 74. Mallinckrodt Company Information Table 75. Mallinckrodt Business Overview Table 76. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 78. Mallinckrodt Recent Development Table 79. Amneal Pharmaceuticals Company Information Table 80. Amneal Pharmaceuticals Business Overview Table 81. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio Table 83. Amneal Pharmaceuticals Recent Development Table 84. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 85. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 86. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 87. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 88. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 90. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 91. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 92. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 93. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 94. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 95. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 96. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 97. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 98. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 99. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 100. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 101. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 102. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 103. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 104. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 105. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 108. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 109. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 110. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 111. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 112. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 113. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 115. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Attention Deficit Hyperactivity Disorder Therapeutics Image Figure 2. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Stimulant Image Figure 5. Non-stimulant Image Figure 6. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacy Image Figure 9. Retail Pharmacy Image Figure 10. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size (US$ Million) & (2021-2032) Figure 11. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Attention Deficit Hyperactivity Disorder Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Type (2021-2032) Figure 18. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Application (2021-2032) Figure 21. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 23. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 24. North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 25. United States Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 30. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 31. Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 32. Germany Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 42. China Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 43. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 45. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Region (2021-2032) Figure 47. Japan Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 55. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 56. SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 57. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Attention Deficit Hyperactivity Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Stimulant
  • Non-stimulant
Applications
  • Hospital Pharmacy
  • Retail Pharmacy
Companies covered
  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Purdue Parma
  • Noven Pharmaceuticals
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Attention Deficit Hyperactivity Disorder Therapeutics Market by Type
  3. 1.2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Stimulant
  5. 1.2.3 Non-stimulant
  6. 1.3 Attention Deficit Hyperactivity Disorder Therapeutics Market by Application
  7. 1.3.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacy
  9. 1.3.3 Retail Pharmacy
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Attention Deficit Hyperactivity Disorder Therapeutics Market Dynamics
  1. 2.1 Attention Deficit Hyperactivity Disorder Therapeutics Industry Trends
  2. 2.2 Attention Deficit Hyperactivity Disorder Therapeutics Industry Drivers
  3. 2.3 Attention Deficit Hyperactivity Disorder Therapeutics Industry Opportunities and Challenges
  4. 2.4 Attention Deficit Hyperactivity Disorder Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Growth Trends by Region
  3. 3.2.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Players
  2. 4.1.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Attention Deficit Hyperactivity Disorder Therapeutics Players, Product Type & Application
  8. 4.5 Global Attention Deficit Hyperactivity Disorder Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Attention Deficit Hyperactivity Disorder Therapeutics Tier 1, Tier 2, and Tier 3
5 Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Type
  1. 5.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Type (2021-2032)
6 Attention Deficit Hyperactivity Disorder Therapeutics Market Size by Application
  1. 6.1 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Attention Deficit Hyperactivity Disorder Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Tris Pharma
  26. 7.5.1 Tris Pharma Company Information
  27. 7.5.2 Tris Pharma Business Overview
  28. 7.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Tris Pharma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  30. 7.5.5 Tris Pharma Recent Developments
  31. 7.6 Purdue Parma
  32. 7.6.1 Purdue Parma Company Information
  33. 7.6.2 Purdue Parma Business Overview
  34. 7.6.3 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Purdue Parma Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  36. 7.6.5 Purdue Parma Recent Developments
  37. 7.7 Noven Pharmaceuticals
  38. 7.7.1 Noven Pharmaceuticals Company Information
  39. 7.7.2 Noven Pharmaceuticals Business Overview
  40. 7.7.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  42. 7.7.5 Noven Pharmaceuticals Recent Developments
  43. 7.8 Neos Therapeutics
  44. 7.8.1 Neos Therapeutics Company Information
  45. 7.8.2 Neos Therapeutics Business Overview
  46. 7.8.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  48. 7.8.5 Neos Therapeutics Recent Developments
  49. 7.9 Mallinckrodt
  50. 7.9.1 Mallinckrodt Company Information
  51. 7.9.2 Mallinckrodt Business Overview
  52. 7.9.3 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Mallinckrodt Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  54. 7.9.5 Mallinckrodt Recent Developments
  55. 7.10 Amneal Pharmaceuticals
  56. 7.10.1 Amneal Pharmaceuticals Company Information
  57. 7.10.2 Amneal Pharmaceuticals Business Overview
  58. 7.10.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder Therapeutics Product Portfolio
  60. 7.10.5 Amneal Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2032)
  2. 8.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country
  11. 8.6.1 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country
  11. 9.6.1 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2032)
  2. 10.2 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country
  11. 11.6.1 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Attention Deficit Hyperactivity Disorder Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst